Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + CACAG in Newly Diagnosed AML
NCT05659992Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Chinese PLA General Hospital. Primary endpoint: Overall Response Rate at 1 month. Started Dec 2022; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05659992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659992.